Diabetic kidney disease: Pathophysiology and therapeutic targets

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Toth Manikowski, Stephanie ^a   Atta, Mohamed G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; ATRASENTAN; AVOSENTAN; AZASERINE; BARDOXOLONE; BENFOTIAMINE; CILOSTAZOL; ETANERCEPT; FG 3019; HEXOSAMINE; INFLIXIMAB; MYCOPHENOLATE MOFETIL; NICORANDIL; PENTOXIFYLLINE; PIOGLITAZONE; PIRFENIDONE; POLYOL; PROTEIN KINASE C; PYRIDOXAMINE; RESVERATROL; RHEIN; ROSIGLITAZONE; RUBOXISTAURIN; SEVELAMER; SILYMARIN; SULODEXIDE; TOLRESTAT; TRANILAST; TURMERIC;

DIABETIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; END STAGE RENAL DISEASE; GLYCATION; GLYCOLYSIS; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); METABOLISM; MULTICENTER STUDY (TOPIC); NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASOCONSTRICTION; DIABETIC NEPHROPATHIES; DRUG EFFECTS; PHYSIOLOGY;

DIABETIC NEPHROPATHIES; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84929325840     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/697010     Document Type: Review

References (190)

1. Number (in Millions) of Civilian, Noninstitutionalized Adults with Diagnosed Diabetes, United States, 1980-2011, http://www.cdc.gov/diabetes/statistics/prev/national/figadults.htm.
2. Centers for Disease Control and Prevention, Annual Number (in Thousands) of New Cases of Diagnosed Diabetes Among Adults Aged 18-79 Years, United States, 1980-2011, Centers for Disease Control and Prevention, 2012, http://www.cdc.gov/diabetes/statistics/incidence/fig1.htm.
3. "USRDS: the United States renal data system", American Journal of Kidney Diseases, vol. 42, no. 6, supplement 5, pp. 1-230, 2003.
4. E. Ritz, I. Rychlik, F. Locatelli, and S. Halimi, "End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions", American Journal of Kidney Diseases, vol. 34, no. 5, pp. 795-808, 1999.
5. A. T. Reutens, "Epidemiology of Diabetic Kidney Disease", Medical Clinics of North America, vol. 97, no. 1, pp. 1-18, 2013.
6. Number of People Initiating Treatment for End-Stage Renal Disease Related to Diabetes Mellitus (ESRD-DM), United States, 1980-2008, http://www.cdc.gov/diabetes/statistics/esrd/fig1.htm.
7. K. Reidy, H. M. Kang, T. Hostetter, and K. Susztak, "Molecular mechanisms of diabetic kidney disease", Journal of Clinical Investigation, vol. 124, no. 6, pp. 2333-2340, 2014.
8. The Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus", The New England Journal of Medicine, vol. 329, no. 14, pp. 977-986, 1993.
9. A. Patel, S. MacMahon, J. Chalmers et al., "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes", The New England Journal of Medicine, vol. 358, no. 24, pp. 2560-2572, 2008.
10. V. Perkovic, H. L. Heerspink, J. Chalmers et al., "Intensive glucose control improves kidney outcomes in patients with type 2 diabetes", Kidney International, vol. 83, no. 3, pp. 517-523, 2013.
11. E. J. Lewis, L. G. Hunsicker, R. P. Bain, R. D. Rohde, and The Collaborative Study Group, "The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy", The New England Journal of Medicine, vol. 329, no. 20, pp. 1456-1462, 1993.
12. P. Ruggenenti, A. Fassi, A. P. Ilieva et al., "Preventing microalbuminuria in type 2 diabetes", The New England Journal of Medicine, vol. 351, no. 19, pp. 1941-1951, 2004.
13. E. J. Lewis, L. G. Hunsicker, W. R. Clarke et al., "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes", The New England Journal of Medicine, vol. 345, no. 12, pp. 851-860, 2001.
14. B. M. Brenner, M. E. Cooper, D. de Zeeuw et al., "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy", The New England Journal of Medicine, vol. 345, no. 12, pp. 861-869, 2001.
15. M. G. Atta, K. Baptiste-Roberts, F. L. Brancati, and T. L. Gary, "The natural course of microalbuminuria among African Americans with type 2 diabetes: a 3-year study", American Journal of Medicine, vol. 122, no. 1, pp. 62-72, 2009.
16. J. Lv, V. Perkovic, C. V. Foote, M. E. Craig, J. C. Craig, and G. F. M. Strippoli, "Antihypertensive agents for preventing diabetic kidney disease", Cochrane Database of Systematic Reviews, vol. 12, Article ID CD004136, 2012.
17. M. E. Molitch, A. I. Adler, A. Flyvbjerg et al., "Diabetic kidney disease: a clinical update from kidney disease: improving global outcomes", Kidney International, vol. 87, pp. 20-30, 2015.
18. A. K. H. Lim, "Diabetic nephropathy-complications and treatment", International Journal of Nephrology and Renovascular Disease, vol. 7, pp. 361-381, 2014.
19. R. Z. Alicic and K. R. Tuttle, "Novel therapies for diabetic kidney disease", Advances in Chronic Kidney Disease, vol. 21, no. 2, pp. 121-133, 2014.
20. M. M. Schwartz, E. J. Lewis, T. Leonard-Martin et al., "Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy", Nephrology Dialysis Transplantation, vol. 13, no. 10, pp. 2547-2552, 1998.
21. R. J. MacIsaac, C. Tsalamandris, S. Panagiotopoulos, T. J. Smith, K. J. McNeil, and G. Jerums, "Nonalbuminuric renal insufficiency in type 2 diabetes", Diabetes Care, vol. 27, no. 1, pp. 195-200, 2004.
22. G. Pugliese, "Updating the natural history of diabetic nephropathy", Acta Diabetologica, vol. 51, no. 6, pp. 905-915, 2014.
23. H. J. Kramer, Q. D. Nguyen, G. Curhan, and C.-Y. Hsu, "Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus", The Journal of the American Medical Association, vol. 289, no. 24, pp. 3273-3277, 2003.
24. P. Fioretto, M. L. Caramori, and M. Mauer, "The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007", Diabetologia, vol. 51, no. 8, pp. 1347-1355, 2008.
25. W. Huang, Y. Gallois, N. Bouby et al., "Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse", Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 23, pp. 13330-13334, 2001.
26. S. Rudberg, L. M. Rasmussen, H.-J. Bangstad, and R. Österby, "Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria", Diabetes Care, vol. 23, no. 4, pp. 544-548, 2000.
27. W. A. Wilmer, L. A. Hebert, E. J. Lewis et al., "Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the captopril study", American Journal of Kidney Diseases, vol. 34, no. 2, pp. 308-314, 1999.
28. K. Benz and K. Amann, "Endothelin in diabetic renal disease", Contributions to Nephrology, vol. 172, pp. 139-148, 2011.
29. M. Brownlee, "Biochemistry and molecular cell biology of diabetic complications", Nature, vol. 414, no. 6865, pp. 813-820, 2001.
30. X.-L. Du, D. Edelstein, L. Rossetti et al., "Hyperglycemiainduced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation", Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 22, pp. 12222-12226, 2000.
31. T. Nishikawa, D. Edelstein, X. L. Du et al., "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage", Nature, vol. 404, no. 6779, pp. 787-790, 2000.
32. P. Beckerman and K. Susztak, "Sweet debate: fructose versus glucose in diabetic kidney disease", Journal of the American Society of Nephrology, vol. 25, no. 11, pp. 2386-2388, 2014.
33. M. A. Lanaspa, T. Ishimoto, C. Cicerchi et al., "Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy", Journal of the American Society of Nephrology, vol. 25, no. 11, pp. 2526-2538, 2014.
34. E. D. Schleicher and C. Weigert, "Role of the hexosamine biosynthetic pathway in diabetic nephropathy", Kidney International Supplements, vol. 77, pp. S13-S18, 2000.
35. S. Chen, B. Jim, and F. N. Ziyadeh", Diabetic nephropathy and transforming growth factor-β: transforming our view of glomerulosclerosis and fibrosis build-up", Seminars in Nephrology, vol. 23, no. 6, pp. 532-543, 2003.
36. M. J. Sheetz and G. L. King, "Molecular understanding of hyperglycemia's adverse effects for diabetic complications", Journal of the American Medical Association, vol. 288, no. 20, pp. 2579-2588, 2002.
37. E. J. Verspohl, "Novel pharmacological approaches to the treatment of type 2 diabetes", Pharmacological Reviews, vol. 64, no. 2, pp. 188-237, 2012.
38. J. M. Forbes, M. E. Cooper, M. D. Oldfield, and M. C. Thomas, "Role of advanced glycation end products in diabetic nephropathy", Journal of the American Society of Nephrology, vol. 14, no. 8, supplement 3, pp. S254-S258, 2003.
39. H.-M. Raabe, J.-H. Höpner, H. Notbohm, G. H. G. Sinnecker, K. Kruse, and P. K. Müller, "Biochemical and biophysical alterations of the 7S and NC1 domain of collagen IV from human diabetic kidneys", Diabetologia, vol. 41, no. 9, pp. 1073-1079, 1998.
40. A. S. Charonis and E. C. Tsilibary, "Structural and functional changes of laminin and type IV collagen after nonenzymatic glycation", Diabetes, vol. 41, supplement 2, pp. 49-51, 1992.
41. H. A. Walton, J. Byrne, and G. B. Robinson, "Studies of the permeation properties of glomerular basement membrane: crosslinking renders glomerular basement membrane permeable to protein", Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1138, no. 3, pp. 173-183, 1992.
42. P. Bai, K. Phua, T. Hardt, M. Cernadas, and B. Brodsky, "Glycation alters collagen fibril organization", Connective Tissue Research, vol. 28, no. 1-2, pp. 1-12, 1992.
43. H. Vlassara, L. J. Striker, S. Teichberg, H. Fuh, Y. M. Li, and M. Steffes, "Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats", Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 24, pp. 11704-11708, 1994.
44. C.-W. Yang, H. Vlassara, E. P. Peten, C.-J. He, G. E. Striker, and L. J. Striker, "Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease", Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 20, pp. 9436-9440, 1994.
45. J.-S. Huang, J.-Y. Guh, H.-C. Chen, W.-C. Hung, Y.-H. Lai, and L.-Y. Chuang, "Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells", Journal of Cellular Biochemistry, vol. 81, no. 1, pp. 102-113, 2001.
46. S. Sakurai, H. Yonekura, Y. Yamamoto et al., "The AGE-RAGE system and diabetic nephropathy", Journal of the American Society of Nephrology, vol. 14, no. 8, supplement 3, pp. S259-S263, 2003.
47. K. Fukami, S.-I. Yamagishi, S. Ueda, and S. Okuda, "Role of AGEs in diabetic nephropathy", Current Pharmaceutical Design, vol. 14, no. 10, pp. 946-952, 2008.
48. Y. Tan, B. Wang, J. S. Keum, and A. A. Jaffa, "Mechanisms through which bradykinin promotes glomerular injury in diabetes", The American Journal of Physiology-Renal Physiology, vol. 288, no. 3, pp. F483-F492, 2005.
49. A. Tufro and D. Veron, "VEGF and podocytes in diabetic nephropathy", Seminars in Nephrology, vol. 32, no. 4, pp. 385-393, 2012.
50. R. M. Mason, "Connective tissue growth factor (CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it?" Journal of Cell Communication and Signaling, vol. 3, no. 2, pp. 95-104, 2009.
51. H. Noh and G. L. King, "The role of protein kinase C activation in diabetic nephropathy", Kidney International, no. 106, pp. S49-S53, 2007.
52. P. A. Craven, C. M. Davidson, and F. R. DeRubertis, "Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids", Diabetes, vol. 39, no. 6, pp. 667-674, 1990.
53. N. Bank and H. S. Aynedjian, "Role of EDRF (nitric oxide) in diabetic renal hyperfiltration", Kidney International, vol. 43, no. 6, pp. 1306-1312, 1993.
54. M. J. Dunn, "Prostaglandin I2 and the kidney", Archives des Maladies du Coeur et des Vaisseaux, vol. 82, no. 4, pp. 27-31, 1989.
55. B. Williams and R. W. Schrier, "Glucose-induced protein kinase C activity regulates arachidonic acid release and eicosanoid production by cultured glomerular mesangial cells", The Journal of Clinical Investigation, vol. 92, no. 6, pp. 2889-2896, 1993.
56. X. Ruan and W. J. Arendshorst, "Role of protein kinase C in angiotensin II-induced renal vasoconstriction in genetically hypertensive rats", American Journal of Physiology, vol. 270, no. 6, part 2, pp. F945-F952, 1996.
57. T. Nagahama, K. Hayashi, Y. Ozawa, T. Takenaka, and T. Saruta, "Role of protein kinase C in angiotensin II-induced constriction of renal microvessels", Kidney International, vol. 57, no. 1, pp. 215-223, 2000.
58. S. S. Prabhakar, "Role of nitric oxide in diabetic nephropathy", Seminars in Nephrology, vol. 24, no. 4, pp. 333-344, 2004.
59. P. Tessari, "Nitric oxide in the normal kidney and in patients with diabetic nephropathy", Journal of Nephrology, 2014.
60. J. Menne, J.-K. Park, M. Boehne et al., "Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-α-deficient diabetic mice", Diabetes, vol. 53, no. 8, pp. 2101-2109, 2004.
61. P. M. García-García, M. A. Getino-Melián, V. Domínguez-Pimentel, and J. F. Navarro-González, "Inflammation in diabetic kidney disease", World Journal of Diabetes, vol. 5, no. 4, pp. 431-443, 2014.
62. J. C. Pickup, "Inflammation and activated innate immunity in the pathogenesis of type 2 diabletes", Diabetes Care, vol. 27, no. 3, pp. 813-823, 2004.
63. A. B. Sanz, M. D. Sanchez-Niño, A. M. Ramos et al., "NF-κB in renal inflammation", Journal of the American Society of Nephrology, vol. 21, no. 8, pp. 1254-1262, 2010.
64. S. Mezzano, C. Aros, A. Droguett et al., "NF-κB activation and overexpression of regulated genes in human diabetic nephropathy", Nephrology Dialysis Transplantation, vol. 19, no. 10, pp. 2505-2512, 2004.
65. S. Ohga, K. Shikata, K. Yozai et al., "Thiazolidinedione ameliorates renal injury in experimental diabetic rats through antiinflammatory effects mediated by inhibition of NF-kappaB activation", The American Journal of Physiology-Renal Physiology, vol. 292, no. 4, pp. F1141-F1150, 2007.
66. N. Sakai, T. Wada, K. Furuichi et al., "p38 MAPK phosphorylation and NF-κB activation in human crescentic glomerulonephritis", Nephrology Dialysis Transplantation, vol. 17, no. 6, pp. 998-1004, 2002.
67. P. Y. Chuang and J. C. He, "JAK/STAT signaling in renal diseases", Kidney International, vol. 78, no. 3, pp. 231-234, 2010.
68. C. C. Berthier, H. Zhang, M. Schin et al., "Enhanced expression of janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy", Diabetes, vol. 58, no. 2, pp. 469-477, 2009.
69. J. F. Navarro, F. J. Milena, C. Mora, C. León, and J. García, "Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration", American Journal of Nephrology, vol. 26, no. 6, pp. 562-570, 2006.
70. K. Sekizuka, Y. Tomino, C. Sei et al., "Detection of serum IL-6 in patients with diabetic nephropathy", Nephron, vol. 68, no. 2, pp. 284-285, 1994.
71. Y. Moriwaki, T. Yamamoto, Y. Shibutani et al., "Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy", Metabolism: Clinical and Experimental, vol. 52, no. 5, pp. 605-608, 2003.
72. J. F. Navarro, C. Mora, M. Muros, and J. García, "Urinary tumour necrosis factor-α excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients", Nephrology Dialysis Transplantation, vol. 21, no. 12, pp. 3428-3434, 2006.
73. J. A. Royall, R. L. Berkow, J. S. Beckman, M. K. Cunningham, S. Matalon, and B. A. Freeman, "Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability", The American Journal of Physiology, vol. 257, no. 6, part 1, pp. L399-L410, 1989.
74. J. F. Navarro-González and C. Mora-Fernández, "The role of inflammatory cytokines in diabetic nephropathy", Journal of the American Society of Nephrology, vol. 19, no. 3, pp. 433-442, 2008.
75. M. D. Vestra, M. Mussap, P. Gallina et al., "Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes", Journal of the American Society of Nephrology, vol. 16, no. 3, pp. S78-S82, 2005.
76. C. Ruef, K. Budde, J. Lacy et al., "Interleukin 6 is an autocrine growth factor for mesangial cells", Kidney International, vol. 38, no. 2, pp. 249-257, 1990.
77. E. Mariño and J. E. Cardier, "Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-α and Fas (CD95)", Cytokine, vol. 22, no. 5, pp. 142-148, 2003.
78. R. J. L. Stuyt, M. G. Netea, T. B. H. Geijtenbeek, B. J. Kullberg, C. A. Dinarello, and J. W. M. van der Meer, "Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes", Immunology, vol. 110, no. 3, pp. 329-334, 2003.
79. T. Bertani, M. Abbate, C. Zoja et al., "Tumor necrosis factor induces glomerular damage in the rabbit", The American Journal of Pathology, vol. 134, no. 2, pp. 419-430, 1989.
80. K. DiPetrillo, B. Coutermarsh, and F. A. Gesek, "Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes", The American Journal of Physiology-Renal Physiology, vol. 284, no. 1, pp. F113-F121, 2003.
81. K. Dipetrillo and F. A. Gesek, "Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats", American Journal of Nephrology, vol. 24, no. 3, pp. 352-359, 2004.
82. H. Ha, I.-A. Hwang, J. H. Park, and H. B. Lee, "Role of reactive oxygen species in the pathogenesis of diabetic nephropathy", Diabetes Research and Clinical Practice, vol. 82, supplement 1, pp. S42-S45, 2008.
83. G. Kroemer, G. Mariño, and B. Levine, "Autophagy and the integrated stress response", Molecular Cell, vol. 40, no. 2, pp. 280-293, 2010.
84. S. Kume, K. Yamahara, M. Yasuda, H. Maegawa, and D. Koya, "Autophagy: emerging therapeutic target for diabetic nephropathy", Seminars in Nephrology, vol. 34, no. 1, pp. 9-16, 2014.
85. R. Singh, S. Kaushik, Y. Wang et al., "Autophagy regulates lipid metabolism", Nature, vol. 458, no. 7242, pp. 1131-1135, 2009.
86. T. Yoshizaki, C. Kusunoki, M. Kondo et al., "Autophagy regulates inflammation in adipocytes", Biochemical and Biophysical Research Communications, vol. 417, no. 1, pp. 352-357, 2012.
87. L. Fang, Y. Zhou, H. Cao et al., "Autophagy attenuates diabetic glomerular damage through protection of hyperglycemiainduced podocyte injury", PLoS ONE, vol. 8, no. 4, Article ID e60546, 2013.
88. K. Yamahara, S. Kume, D. Koya et al., "Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions", Journal of the American Society of Nephrology, vol. 24, no. 11, pp. 1769-1781, 2013.
89. M. Kitada, A. Takeda, T. Nagai, H. Ito, K. Kanasaki, and D. Koya, "Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of sirt1 in diabetic wistar fatty (fa/fa) rats: a model of type 2 diabetes", Experimental Diabetes Research, vol. 2011, Article ID 908185, 11 pages, 2011.
90. G. Vlotides and P. R. Mertens, "Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease", Nephrology Dialysis Transplantation, 2014.
91. Y. Kanai, W. S. Lee, G. You, D. Brown, and M. A. Hediger, "The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose", Journal of Clinical Investigation, vol. 93, no. 1, pp. 397-404, 1994.
92. M. Kamran, R. G. Peterson, and J. H. Dominguez, "Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats", Journal of the American Society of Nephrology, vol. 8, no. 6, pp. 943-948, 1997.
93. S. Dhein, S. Hochreuther, C. A. D. Spring, K. Bollig, C. Hufnagel, and M. Raschack, "Long-term effects of the endothelin (A) receptor antagonist LU 135252 and the angiotensinconverting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model", Journal of Pharmacology and Experimental Therapeutics, vol. 293, no. 2, pp. 351-359, 2000.
94. A. M. D. Watson, J. Li, C. Schumacher et al., "The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein e knockout mice", Diabetologia, vol. 53, no. 1, pp. 192-203, 2010.
95. J. F. E. Mann, D. Green, K. Jamerson et al., "Avosentan for overt diabetic nephropathy", Journal of the American Society of Nephrology, vol. 21, no. 3, pp. 527-535, 2010.
96. J. Hoekman, H. J. Lambers Heerspink, G. Viberti, D. Green, J. F. E. Mann, and D. De Zeeuw, "Predictors of congestive heart failure after treatment with an endothelin receptor antagonist", Clinical Journal of the American Society of Nephrology, vol. 9, no. 3, pp. 490-498, 2014.
97. D. de Zeeuw, B. Coll, D. Andress et al., "The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy", Journal of the American Society of Nephrology, vol. 25, no. 5, pp. 1083-1093, 2014.
98. Study of Diabetic Nephropathy with Atrasentan (SONAR), http://clinicaltrials.gov/ct2/show/NCT01858532?term=nct01858532&rank=1.
99. I. Itagaki, K. Shimizu, Y. Kamanaka et al., "The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats", Diabetes Research and Clinical Practice, vol. 25, no. 3, pp. 147-154, 1994.
100. S. Isogai, T. Inokuchi, and K. Ohe, "Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats", Diabetes Research and Clinical Practice, vol. 30, no. 2, pp. 111-116, 1995.
101. K. Iso, H. Tada, K. Kuboki, and T. Inokuchi, "Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients", Journal of Diabetes and its Complications, vol. 15, no. 5, pp. 241-244, 2001.
102. N. Passariello, J. Sepe, G. Marrazzo et al., "Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy", Diabetes Care, vol. 16, no. 5, pp. 789-795, 1993.
103. WHO Pharmaceuticals Newsletter 1997, No. 03&04, 1997, http://apps.who.int/medicinedocs/en/d/Js2255e/1.18.html#Js2255e.1.18.
104. A. G. Rajapakse, X.-F. Ming, J. M. Carvas, and Z. Yang, "The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects", The American Journal of Physiology-Heart and Circulatory Physiology, vol. 296, no. 3, pp. H815-H822, 2009.
105. S. Z. Safi, R. Qvist, S. Kumar, K. Batumalaie, and I. S. Ismail, "Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets", BioMed Research International, vol. 2014, Article ID 801269, 18 pages, 2014.
106. J. M. Zheng, J. M. Zhu, L. S. Li, and Z. H. Liu, "Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway", British Journal of Pharmacology, vol. 153, no. 7, pp. 1456-1464, 2008.
107. H.-P. Hammes, X. Du, D. Edelstein et al., "Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy", Nature Medicine, vol. 9, no. 3, pp. 294-299, 2003.
108. P. Balakumar, A. Rohilla, P. Krishan, P. Solairaj, and A. Thangathirupathi, "The multifaceted therapeutic potential of benfotiamine", Pharmacological Research, vol. 61, no. 6, pp. 482-488, 2010.
109. N. Karachalias, R. Babaei-Jadidi, N. Ahmed, and P. J. Thornalley, "Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats", Biochemical Society Transactions, vol. 31, no. 6, pp. 1423-1425, 2003.
110. P. Balakumar, V. A. Chakkarwar, and M. Singh, "Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat", Molecular and Cellular Biochemistry, vol. 320, no. 1-2, pp. 149-162, 2009.
111. A. Alkhalaf, A. Klooster, W. van Oeveren et al., "A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy", Diabetes Care, vol. 33, no. 7, pp. 1598-1601, 2010.
112. P. J. Thornalley, "Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts", Archives of Biochemistry and Biophysics, vol. 419, no. 1, pp. 31-40, 2003.
113. T. Soulis-Liparota, M. Cooper, D. Papazoglou, B. Clarke, and G. Jerums, "Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat", Diabetes, vol. 40, no. 10, pp. 1328-1334, 1991.
114. W. K. Bolton, D. C. Cattran, M. E. Williams et al., "Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy", American Journal of Nephrology, vol. 24, no. 1, pp. 32-40, 2004.
115. B. I. Freedman, J.-P. Wuerth, K. Cartwright et al., "Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II)", Controlled Clinical Trials, vol. 20, no. 5, pp. 493-510, 1999.
116. A clinical trail in overt nephropathy (ACTION), 2014, http://www.bsc.gwu.edu/bsc/oneproj.php?pkey=3.
117. P. A. Voziyan, R. G. Khalifah, C. Thibaudeau et al., "Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of amadori intermediate to advanced glycation end-products through binding of redox metal ions", Journal of Biological Chemistry, vol. 278, no. 47, pp. 46616-46624, 2003.
118. M. E. Williams, W. K. Bolton, R. G. Khalifah, T. P. Degenhardt, R. J. Schotzinger, and J. B. McGill, "Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy", American Journal of Nephrology, vol. 27, no. 6, pp. 605-614, 2007.
119. E. J. Lewis, T. Greene, S. Spitalewiz et al., "Pyridorin in type 2 diabetic nephropathy", Journal of the American Society of Nephrology, vol. 23, no. 1, pp. 131-136, 2012.
120. Pyridorin in Diabetic Nephropathy (PIONEER), https://clinicaltrials.gov/ct2/show/NCT02156843?term=NCT02156843&rank=1.
121. Q. Ma, "Role of Nrf2 in oxidative stress and toxicity", Annual Review of Pharmacology and Toxicology, vol. 53, pp. 401-426, 2013.
122. P. E. Pergola, P. Raskin, R. D. Toto et al., "Bardoxolone methyl and kidney function in CKD with type 2 diabetes", The New England Journal of Medicine, vol. 365, no. 4, pp. 327-336, 2011.
123. D. de Zeeuw, T. Akizawa, P. Audhya et al., "Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease", The New England Journal of Medicine, vol. 369, no. 26, pp. 2492-2503, 2013.
124. H. Vlassara, J. Uribarri, W. Cai et al., "Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease", Clinical Journal of the American Society of Nephrology, vol. 7, no. 6, pp. 934-942, 2012.
125. V. Masola, M. Onisto, G. Zaza, A. Lupo, and G. Gambaro, "A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition", Journal of Translational Medicine, vol. 10, no. 1, article 213, 2012.
126. N. Gil, R. Goldberg, T. Neuman et al., "Heparanase is essential for the development of diabetic nephropathy in mice", Diabetes, vol. 61, no. 1, pp. 208-216, 2012.
127. E. J. Lewis and X. Xu, "Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin", Diabetes Care, vol. 31, supplement 2, pp. S202-S207, 2008.
128. R. Goldberg, A. M. Rubinstein, N. Gil et al., "Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy", Diabetes, vol. 63, no. 12, pp. 4302-4313, 2014.
129. G. Gambaro, I. Kinalska, A. Oksa et al., "Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di. N. A. S. randomized trial", Journal of the American Society of Nephrology, vol. 13, no. 6, pp. 1615-1625, 2002.
130. E. J. Lewis, J. B. Lewis, T. Greene et al., "Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial", American Journal of Kidney Diseases, vol. 58, no. 5, pp. 729-736, 2011.
131. D. K. Packham, R. Wolfe, A. T. Reutens et al., "Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy", Journal of the American Society of Nephrology, vol. 23, no. 1, pp. 123-130, 2012.
132. Y. Chen, L. L. Fu, X. Wen et al., "Sirtuin-3(SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer", Cell Death & Disease, vol. 5, no. 2, Article ID e1047, 2014.
133. T. Shiraishi, Y. Tamura, K. Taniguchi et al., "Combination of ACE inhibitor with nicorandil provides further protection in chronic kidney disease", American Journal of Physiology-Renal Physiology, vol. 307, no. 12, pp. F1313-F1322, 2014.
134. K. Tanabe, M. A. Lanaspa, W. Kitagawa et al., "Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse", The American Journal of Physiology-Renal Physiology, vol. 302, no. 9, pp. F1151-F1161, 2012.
135. J. H. Lee, G. T. Oh, S. Y. Park et al., "Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-α formation in low-density lipoprotein receptor-null mice fed high cholesterol", Journal of Pharmacology and Experimental Therapeutics, vol. 313, no. 2, pp. 502-509, 2005.
136. W.-C. Lee, H.-C. Chen, C.-Y. Wang et al., "Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-β and NF-κB", Bioscience, Biotechnology and Biochemistry, vol. 74, no. 7, pp. 1355-1361, 2010.
137. X.-M. Jiao, X.-J. Jiao, X.-G. Zhang et al., "Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy", Chinese Medical Journal, vol. 126, no. 22, pp. 4395-4396, 2013.
138. W.-H. Tang, F.-H. Lin, C.-H. Lee et al., "Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial", Endocrine, vol. 45, no. 2, pp. 293-301, 2014.
139. S. P. RamachandraRao, Y. Zhu, T. Ravasi et al., "Pirfenidone is renoprotective in diabetic kidney disease", Journal of the American Society of Nephrology, vol. 20, no. 8, pp. 1765-1775, 2009.
140. K. Sharma, J. H. Ix, A. V. Mathew et al., "Pirfenidone for diabetic nephropathy", Journal of the American Society of Nephrology, vol. 22, no. 6, pp. 1144-1151, 2011.
141. J. Soma, K. Sato, H. Saito, and Y. Tsuchiya, "Effect of tranilast in early-stage diabetic nephropathy", Nephrology Dialysis Transplantation, vol. 21, no. 10, pp. 2795-2799, 2006.
142. A.-E. Declèves and K. Sharma, "Novel targets of antifibrotic and anti-inflammatory treatment in CKD", Nature Reviews Nephrology, vol. 10, no. 5, pp. 257-267, 2014.
143. S. G. Adler, S. Schwartz, M. E. Williams et al., "Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria", Clinical Journal of the American Society of Nephrology, vol. 5, no. 8, pp. 1420-1428, 2010.
144. Study of FG-3019 in Subjects with Type 2 DM and KD on ACEi and/or ARB therapy, http://clinicaltrials.gov/ct2/show/NCT00913393.
145. Phase 1 Study of FG-3019 in Subjects with Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy, https://clinicaltrials.gov/ct2/show/study/NCT00754143.
146. H. Ishii, M. R. Jirousek, D. Koya et al., "Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor", Science, vol. 272, no. 5262, pp. 728-731, 1996.
147. D. Koya, M. Haneda, H. Nakagawa et al., "Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes", The FASEB Journal, vol. 14, no. 3, pp. 439-447, 2000.
148. K. R. Tuttle, G. L. Bakris, R. D. Toto, J. B. McGill, K. Hu, and P. W. Anderson, "The effect of ruboxistaurin on nephropathy in type 2 diabetes", Diabetes Care, vol. 28, no. 11, pp. 2686-2690, 2005.
149. R. E. Gilbert, S. A. Kim, K. R. Tuttle et al., "Effect of ruboxistaurin on urinary transforming growth factor-β in patients with diabetic nephropathy and type 2 diabetes", Diabetes Care, vol. 30, no. 4, pp. 995-996, 2007.
150. J. Lechleiter and L. P. Aiello, "Ruboxistaurin's future in doubt, despite promising study results", http://escrs.org/PUBLICATIONS/EUROTIMES/07May/Ruboxistaurinsfuturein. pdf.
151. F. Pistrosch, J. Passauer, K. Herbrig, U. Schwanebeck, P. Gross, and S. R. Bornstein, "Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy", Hormone and Metabolic Research, vol. 44, no. 12, pp. 914-918, 2012.
152. Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy, http://clinicaltrials.gov/ct2/show/NCT01175486? term=rosiglitazone+diabetic+nephropathy&rank=4.
153. Z. Zhang, W. Yuan, L. Sun et al., "1, 25-dihydroxyvitamin D3 targeting of NF-κB suppresses high glucose-induced MCP-1 expression in mesangial cells", Kidney International, vol. 72, no. 2, pp. 193-201, 2007.
154. Y. Huang, H. Yu, J. Lu et al., "Oral supplementation with cholecalciferol 800 IU ameliorates albuminuria in Chinese type 2 diabetic patients with nephropathy", PLoS ONE, vol. 7, no. 11, Article ID e50510, 2012.
155. S. Bonakdaran, M. Hami, and A. Hatefi, "The effects of calcitriol on albuminuria in patients with type-2 diabetes mellitus.", Saudi Journal of kidney Diseases and Transplantation, vol. 23, no. 6, pp. 1215-1220, 2012.
156. U. Krairittichai, R. Mahannopkul, and S. Bunnag, "An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease", Journal of the Medical Association of Thailand, vol. 95, supplement 3, pp. S41-S47, 2012.
157. G. Ortiz-Muñoz, V. Lopez-Parra, O. Lopez-Franco et al., "Suppressors of cytokine signaling abrogate diabetic nephropathy", Journal of the American Society of Nephrology, vol. 21, no. 5, pp. 763-772, 2010.
158. A Study to Test Safety and Efficacy of Baricitinib in Participants with Diabetic Kidney Disease, https://clinicaltrials.gov/show/NCT01683409.
159. R. Utimura, C. K. Fujihara, A. L. Mattar, D. M. A. C. Malheiros, I. D. L. Noronha, and R. Zatz, "Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes", Kidney International, vol. 63, no. 1, pp. 209-216, 2003.
160. B. Rodríguez-Iturbe, Y. Quiroz, A. Shahkarami, Z. Li, and N. D. Vaziri, "Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat", Kidney International, vol. 68, no. 3, pp. 1041-1047, 2005.
161. K. Omote, T. Gohda, M. Murakoshi et al., "Role of the TNF pathway in the progression of diabetic nephropathy in KK-Aγ mice", American Journal of Physiology-Renal Physiology, vol. 306, no. 11, pp. F1335-F1347, 2014.
162. Y. Moriwaki, T. Inokuchi, A. Yamamoto et al., "Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats", Acta Diabetologica, vol. 44, no. 4, pp. 215-218, 2007.
163. M. E. Dávila-Esqueda, A. A. Vertiz-Hernández, and F. Martínez-Morales, "Comparative analysis of the renoprotective effects of pentoxifylline and vitamin E on streptozotocininduced diabetes mellitus", Renal Failure, vol. 27, no. 1, pp. 115-122, 2005.
164. S. B. Solerte, M. Fioravanti, A. Bozzetti et al., "Pentoxifylline, albumin excretion rate and proteinuria in type I and type II diabetic patients with microproteinuria. Results of a short-term randomized study", Acta Diabetologia Latina, vol. 23, no. 2, pp. 171-177, 1986.
165. F. Guerrero-Romero, M. Rodríguez-Morán, J. R. Paniagua-Sierra, G. García-Bulnes, M. Salas-Ramírez, and D. Amato, "Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients", Clinical Nephrology, vol. 43, no. 2, pp. 116-121, 1995.
166. J. F. Navarro, C. Mora, A. Rivero et al., "Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration", The American Journal of Kidney Diseases, vol. 33, no. 3, pp. 458-463, 1999.
167. B. B. McCormick, A. Sydor, A. Akbari, D. Fergusson, S. Doucette, and G. Knoll, "The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis", American Journal of Kidney Diseases, vol. 52, no. 3, pp. 454-463, 2008.
168. A. Aminorroaya, M. Janghorbani, H. Rezvanian, T. Aminian, M. Gharavi, and M. Amini, "Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus", Nephron Clinical Practice, vol. 99, no. 3, pp. c73-c77, 2005.
169. J. Roozbeh, M. A. Banihashemi, M. Ghezlou et al., "Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy", Renal Failure, vol. 32, no. 2, pp. 172-178, 2010.
170. J. F. Navarro, C. Mora, M. Muros, and J. García, "Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial", Journal of the American Society of Nephrology, vol. 16, no. 7, pp. 2119-2126, 2005.
171. M. K. Fallahzadeh, B. Dormanesh, M. M. Sagheb et al., "Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial", American Journal of Kidney Diseases, vol. 60, no. 6, pp. 896-903, 2012.
172. J. Gaedeke, N. A. Noble, and W. A. Border, "Curcumin blocks multiple sites of the TGF-β signaling cascade in renal cells", Kidney International, vol. 66, no. 1, pp. 112-120, 2004.
173. Y. S. Kim, Y. Ahn, M. H. Hong et al., "Curcumin attenuates inflammatory responses of TNF-α-stimulated human endothelial cells", Journal of Cardiovascular Pharmacology, vol. 50, no. 1, pp. 41-49, 2007.
174. P. Khajehdehi, M. Pakfetrat, K. Javidnia et al., "Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study", Scandinavian Journal of Urology and Nephrology, vol. 45, no. 5, pp. 365-370, 2011.
175. Effect of Green Tea (Epigallocatechin Gallate) on Albuminuria in Patients with Diabetic Nephropathy, http://clinicaltrials.gov/show/NCT01923597.
176. A. N. Friedman, M. Chambers, L. M. Kamendulis, and J. Temmerman, "Short-term changes after a weight reduction intervention in advanced diabetic nephropathy", Clinical Journal of the American Society of Nephrology, vol. 8, no. 11, pp. 1892-1898, 2013.
177. S. Kume, M. Kitada, K. Kanasaki, H. Maegawa, and D. Koya, "Anti-aging molecule, Sirt1: a novel therapeutic target for diabetic nephropathy", Archives of Pharmacal Research, vol. 36, no. 2, pp. 230-236, 2013.
178. S. Sharma, M. Anjaneyulu, S. K. Kulkarni, and K. Chopra, "Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats", Pharmacology, vol. 76, no. 2, pp. 69-75, 2006.
179. P. Palsamy and S. Subramanian, "Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling", Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1812, no. 7, pp. 719-731, 2011.
180. M. Kitada, S. Kume, N. Imaizumi, and D. Koya, "Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway", Diabetes, vol. 60, no. 2, pp. 634-643, 2011.
181. L. de Nicola, F. B. Gabbai, M. E. Liberti, A. Sagliocca, G. Conte, and R. Minutolo, "Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes", American Journal of Kidney Diseases, vol. 64, no. 1, pp. 16-24, 2014.
182. A. M. Brooks and S. M. Thacker, "Dapagliflozin for the treatment of type 2 diabetes", Annals of Pharmacotherapy, vol. 43, no. 7-8, pp. 1286-1293, 2009.
183. J. F. List, V. Woo, E. Morales, W. Tang, and F. T. Fiedorek, "Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes", Diabetes Care, vol. 32, no. 4, pp. 650-657, 2009.
184. J. P. H. Wilding, V. Woo, N. G. Soler et al., "Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin a randomized trial", Annals of Internal Medicine, vol. 156, no. 6, pp. 405-415, 2012.
185. D. E. Kohan, P. Fioretto, W. Tang, and J. F. List, "Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control", Kidney International, vol. 85, no. 4, pp. 962-971, 2014.
186. W. T. Cefalu, L. A. Leiter, K.-H. Yoon et al., "Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, doubleblind, phase 3 non-inferiority trial", The Lancet, vol. 382, no. 9896, pp. 941-950, 2013.
187. J.-F. Yale, G. Bakris, B. Cariou et al., "Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease", Diabetes, Obesity and Metabolism, vol. 16, no. 10, pp. 1016-1027, 2014.
188. M. C. Thomas, R. J. MacIsaac, G. Jerums et al., "Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11", Diabetes Care, vol. 32, no. 8, pp. 1497-1502, 2009.
189. E. Lurbe, J. Redon, A. Kesani et al., "Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes", The New England Journal of Medicine, vol. 347, no. 11, pp. 797-805, 2002.
190. S. G. Sharma, A. S. Bomback, J. Radhakrishnan et al., "The modern spectrum of renal biopsy findings in patients with diabetes", Clinical Journal of the American Society of Nephrology, vol. 8, no. 10, pp. 1718-1724, 2013.